title: The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
abstract: Components of cell signaling pathways provide important targets for anticancer drugs. Protein kinase C (PKC) is a serine/threonine-specific kinase that regulates cell growth and differentiation. It is also implicated in tumor promotion. The staurosporine analogue CGP41251 is a PKC inhibitor, and it is currently in a Phase I clinical trial for treatment of advanced cancer. However, it is difficult to define its biological activity. We have used two approaches to measure the in vivo biological response to CGP41251: (a) sequential whole blood samples were taken from 27 patients before and during treatment and incubated with mitogen (PHA), and cytokine [tumor necrosis factor (TNF)-alpha and interleukin (IL)-6] release was measured ex vivo; and (b) peripheral blood lymphocytes were isolated from seven of these patients, and the levels of extracellular signal-regulated kinase 2 were measured by Western blotting. Response to PHA was significantly lowered during treatment (P < 0.001 for TNF-alpha production; P < 0.03 for IL-6). This was most evident at 7 and 28 days after the start of treatment in patients receiving higher doses (150-300 mg/day; P = 0.002 and P = 0.02, respectively, for TNF-alpha and P = 0.001 and P = 0.003, respectively, for IL-6 release). Whole blood cytokine production returned to pretreatment levels after drug administration ceased. The levels of extracellular signal-regulated kinase 2 were reduced by 50-97% during treatment in all seven patients tested. These results show for the first time that a PKC inhibitor can block in vivo signaling pathways in cancer patients. The assays we describe complement toxicity studies in selecting relevant doses for Phase II trial of novel agents, particularly when biological activity occurs at doses below those that cause obvious side effects.
authors.affiliation: Imperial Cancer Research Fund, London, United Kingdom.
authors.forename: P
authors.initials: P
authors.lastname: Thavasu
authors.forename: D
authors.initials: D
authors.lastname: Propper
authors.forename: A
authors.initials: A
authors.lastname: McDonald
authors.forename: N
authors.initials: N
authors.lastname: Dobbs
authors.forename: T
authors.initials: T
authors.lastname: Ganesan
authors.forename: D
authors.initials: D
authors.lastname: Talbot
authors.forename: J
authors.initials: J
authors.lastname: Braybrook
authors.forename: F
authors.initials: F
authors.lastname: Caponigro
authors.forename: C
authors.initials: C
authors.lastname: Hutchison
authors.forename: C
authors.initials: C
authors.lastname: Twelves
authors.forename: A
authors.initials: A
authors.lastname: Man
authors.forename: D
authors.initials: D
authors.lastname: Fabbro
authors.forename: A
authors.initials: A
authors.lastname: Harris
authors.forename: F
authors.initials: F
authors.lastname: Balkwill
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000097:blood*; D016207:Cytokines / Q000097:blood*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism; D008875:Middle Aged; D019950:Mitogen-Activated Protein Kinase 1; D009369:Neoplasms / Q000097:blood* / Q000188:drug therapy*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D019311:Staurosporine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D011493:Protein Kinase C; D017871:Calcium-Calmodulin-Dependent Protein Kinases; D019950:Mitogen-Activated Protein Kinase 1; D019311:Staurosporine; C059539:midostaurin